Last reviewed · How we verify
NCT05659927
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
Phase 1 trial testing MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma in 34 participants. Status unknown.
26 January 2024
Quick facts
| Lead sponsor | Shanghai Mabgeek Biotech.Co.Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 9 February 2023 |
| Primary completion | 26 January 2024 |
| Estimated completion | 23 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- MG-ZG122 Humanized Monoclonal Antibody Injection — full drug profile →
- Placebo
Conditions studied
- Asthma — all drugs for Asthma →
Sponsor
Shanghai Mabgeek Biotech.Co.Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05659927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MG-ZG122 Humanized Monoclonal Antibody Injection
Trials testing the same drug.
- NCT07054034 — Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects · Phase 2 · active not recruiting
Other recruiting trials for Asthma
Currently open trials in the same condition.
- NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
- NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
- NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
- NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
- NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting
Other Shanghai Mabgeek Biotech.Co.Ltd trials
Trials by the same sponsor.
- NCT07103174 — A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis · Phase 2 · not yet recruiting
- NCT07054034 — Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects · Phase 2 · active not recruiting
- NCT06837922 — Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma · Phase 3 · recruiting
- NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
- NCT06026891 — Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05659927 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mabgeek Biotech.Co.Ltd
- Last refreshed: 23 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05659927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing